Your browser is no longer supported. Please, upgrade your browser.
EGRX [NASD]
Eagle Pharmaceuticals, Inc.
Index- P/E49.90 EPS (ttm)0.89 Insider Own12.30% Shs Outstand13.06M Perf Week7.55%
Market Cap580.46M Forward P/E11.03 EPS next Y4.02 Insider Trans0.00% Shs Float10.12M Perf Month-1.03%
Income12.00M PEG18.48 EPS next Q0.74 Inst Own95.30% Short Float13.86% Perf Quarter-10.58%
Sales187.80M P/S3.09 EPS this Y-14.00% Inst Trans-3.13% Short Ratio11.25 Perf Half Y-3.08%
Book/sh14.24 P/B3.11 EPS next Y22.58% ROA4.30% Target Price48.00 Perf Year-7.76%
Cash/sh7.88 P/C5.62 EPS next 5Y2.70% ROE6.60% 52W Range36.48 - 56.16 Perf YTD-4.85%
Dividend- P/FCF11.89 EPS past 5Y40.60% ROI10.20% 52W High-20.83% Beta0.79
Dividend %- Quick Ratio4.10 Sales past 5Y23.20% Gross Margin75.80% 52W Low21.87% ATR1.51
Employees106 Current Ratio4.40 Sales Q/Q3.30% Oper. Margin17.50% RSI (14)57.98 Volatility3.09% 3.73%
OptionableYes Debt/Eq0.18 EPS Q/Q748.50% Profit Margin6.40% Rel Volume0.50 Prev Close44.31
ShortableYes LT Debt/Eq0.13 EarningsMar 02 BMO Payout0.00% Avg Volume124.68K Price44.46
Recom2.20 SMA205.07% SMA500.25% SMA200-2.18% Volume34,260 Change0.34%
Apr-07-21Resumed RBC Capital Mkts Outperform $52
Nov-01-18Downgrade Cantor Fitzgerald Overweight → Neutral
Oct-31-18Downgrade Piper Jaffray Overweight → Neutral
Mar-21-18Reiterated Mizuho Underperform $37 → $40
Nov-09-17Reiterated RBC Capital Mkts Outperform $81 → $75
Sep-06-17Reiterated Mizuho Underperform $40 → $37
Jul-27-17Reiterated RBC Capital Mkts Outperform $94 → $81
Jul-27-17Reiterated Mizuho Underperform $57 → $40
May-09-17Reiterated RBC Capital Mkts Outperform $86 → $94
Jan-09-17Downgrade Mizuho Neutral → Underperform $78 → $64
Nov-16-16Downgrade Mizuho Buy → Neutral $78
Nov-03-16Upgrade Mizuho Neutral → Buy $62 → $78
Nov-03-16Reiterated RBC Capital Mkts Outperform $80 → $93
Oct-26-16Reiterated Mizuho Buy $65 → $62
Aug-16-16Reiterated Mizuho Neutral $47 → $65
Jun-20-16Downgrade Mizuho Buy → Neutral $66 → $47
May-10-16Reiterated RBC Capital Mkts Outperform $94 → $78
Mar-18-16Reiterated Mizuho Buy $81 → $71
Feb-26-16Reiterated Mizuho Buy $112 → $81
Dec-09-15Initiated Mizuho Buy $112
Apr-15-21 03:22AM  
Mar-15-21 04:08PM  
Mar-03-21 12:23AM  
Mar-02-21 02:00PM  
08:15AM  
06:50AM  
06:30AM  
Mar-01-21 10:15AM  
Feb-22-21 04:30PM  
Feb-02-21 07:45AM  
06:50AM  
Feb-01-21 06:50AM  
Jan-11-21 06:50AM  
Jan-04-21 04:30PM  
Jan-03-21 02:45AM  
Dec-15-20 07:27PM  
Nov-23-20 06:50AM  
Nov-04-20 06:10AM  
Nov-02-20 12:30PM  
08:24AM  
08:05AM  
06:47AM  
06:45AM  
Oct-26-20 04:30PM  
Oct-15-20 09:20AM  
08:19AM  
Sep-25-20 02:13PM  
Sep-24-20 11:30AM  
11:30AM  
06:50AM  
Sep-23-20 06:50AM  
Sep-09-20 11:07AM  
Sep-08-20 06:50AM  
Aug-19-20 06:50AM  
Aug-10-20 01:30PM  
08:15AM  
07:06AM  
06:50AM  
Aug-03-20 04:30PM  
Jul-31-20 03:56PM  
Jul-17-20 11:47AM  
Jul-09-20 12:00PM  
Jun-27-20 09:28PM  
Jun-10-20 04:08PM  
May-26-20 04:30PM  
May-22-20 04:05PM  
May-14-20 11:50AM  
May-12-20 04:30PM  
May-11-20 12:30PM  
08:35AM  
08:14AM  
07:22AM  
06:50AM  
May-08-20 08:41AM  
May-07-20 06:07AM  
May-04-20 06:50AM  
Apr-29-20 04:30PM  
Apr-28-20 12:33PM  
06:50AM  
Apr-16-20 05:24PM  
06:50AM  
Apr-11-20 09:25AM  
Mar-30-20 06:50AM  
Mar-24-20 02:20AM  
Mar-10-20 07:55AM  
Mar-02-20 08:15AM  
06:50AM  
Feb-24-20 12:30PM  
Feb-19-20 04:30PM  
Feb-13-20 07:50AM  
Feb-10-20 09:54AM  
Jan-13-20 06:50AM  
Jan-09-20 08:40AM  
06:50AM  
Jan-08-20 10:18AM  
08:16AM  
Jan-07-20 09:25AM  
07:20AM  
Jan-06-20 06:50AM  
Dec-23-19 06:50AM  
Dec-16-19 06:50AM  
Dec-13-19 02:53PM  
Dec-11-19 11:25AM  
Dec-09-19 06:50AM  
Dec-03-19 08:45AM  
Nov-21-19 07:49AM  
Nov-20-19 06:50AM  
Nov-14-19 06:50AM  
Nov-12-19 08:15AM  
06:51AM  
06:50AM  
Nov-09-19 02:26PM  
Nov-05-19 10:31AM  
Oct-31-19 04:30PM  
10:34AM  
Oct-28-19 08:02AM  
Oct-17-19 09:28AM  
Oct-07-19 06:50AM  
Oct-02-19 02:39PM  
Sep-24-19 11:30AM  
Eagle Pharmaceuticals, Inc., a biotechnology pharmaceutical company, focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has a strategic collaboration with Tyme Technologies, Inc. to advance oral SM-88 for the treatment of patients with cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RATOFF STEVEN BDirectorApr 08Option Exercise7.337,02051,43327,364Apr 12 04:38 PM
Tarriff ScottCEOApr 01Option Exercise8.7831,201273,9451,561,184Apr 05 04:54 PM